May enhance risk of hemorrhage. Discontinue prior to Lovenox initiation if possible, or conduct close clinical and laboratory monitoring if coadministration is essential.
Source: NLP:enoxaparin sodium
Salicylates Interactions
33 interactions on record
High-dose salicylates with furosemide may cause salicylate toxicity at lower doses due to competitive renal excretion.
Source: NLP:furosemide
Caution should be used when salicylates are administered concomitantly with methotrexate. These drugs reduce tubular secretion of methotrexate and may displace it from serum albumin binding, enhancing toxicity.
Source: NLP:methotrexate
Administration of monobasic phosphates may lead to toxic salicylate levels due to decreased excretion in acidified urine.
Source: NLP:potassium phosphate, monobasic and sodium phosphate, monobasic, anhydrous
Concomitant use increases gastrointestinal side effects; clearance of salicylates may be increased.
Source: NLP:prednisolone sodium phosphate
Compete for renal tubular secretion; high-dose salicylates may experience salicylate toxicity when given with torsemide.
Source: NLP:torsemide
Potential for acid-base and electrolyte disturbances that could result in toxicity with high-dose salicylate therapy.
Source: NLP:dorzolamide hydrochloride
Potential for acid-base and electrolyte disturbances and toxicity with high-dose salicylate therapy.
Source: NLP:dorzolamide hydrochloride timolol maleate
May increase phenytoin serum levels; monitoring of phenytoin levels recommended.
Source: NLP:fosphenytoin sodium
Salicylates + GlibenclamideModerate
May potentiate hypoglycemic action of glyburide; patient should be closely observed for hypoglycemia.
Source: NLP:glyburide
Salicylates + GlimepirideModerate
Highly protein-bound drugs that may increase glucose-lowering effect of glimepiride, increasing susceptibility to hypoglycemia.
Source: NLP:glimepiride
Salicylates + GlipizideModerate
Salicylates may potentiate hypoglycemic action of glipizide. Caution should be exercised; in vitro studies suggest glipizide does not interact with salicylate but clinical extrapolation warranted.
Source: NLP:glipizide
May potentiate hypoglycemic action of glyburide; monitor closely for hypoglycemia.
Source: NLP:glyburide and metformin hydrochloride
May potentiate hypoglycemic action of glyburide; monitor for hypoglycemia.
Source: NLP:glyburide-metformin hydrochloride
Salicylates + GriseofulvinModerate
Serum salicylate concentrations may be decreased when griseofulvin is given concomitantly.
Source: NLP:griseofulvin
Salicylates + HyaluronidaseModerate
Large doses of salicylates may require larger amounts of hyaluronidase for equivalent dispersing effect; these drugs render tissues partly resistant to hyaluronidase action.
Source: NLP:hyaluronidase
May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.
Source: NLP:insulin aspart
May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.
Source: NLP:insulin aspart-szjj
Salicylates + Insulin DegludecModerate
May increase risk of hypoglycemia. Dosage reductions and increased glucose monitoring may be required.
Source: NLP:insulin degludec
Salicylates + Insulin GlargineModerate
May increase risk of hypoglycemia; dosage reductions and increased glucose monitoring may be required.
Source: NLP:insulin glargine
Salicylates + Insulin GlulisineModerate
May increase risk of hypoglycemia. Dose adjustment and increased glucose monitoring may be required.
Source: NLP:insulin glulisine
Salicylates + Insulin HumanModerate
May increase risk of hypoglycemia; dose adjustment and increased glucose monitoring may be required.
Source: NLP:insulin human
Salicylates + Insulin LisproModerate
May increase the risk of hypoglycemia. Dose adjustment and increased frequency of glucose monitoring may be required.
Source: NLP:insulin lispro
May increase risk of hypoglycemia. Dose reductions and increased glucose monitoring may be required.
Source: NLP:insulin lispro-aabc
At therapeutic concentrations, salicylate reduces ketorolac protein binding from 99.2% to 97.5%, representing potential two-fold increase in unbound ketorolac plasma levels.
Source: NLP:ketorolac tromethamine
At doses >2 g/day, inhibit binding of T4 and T3 to TBG and transthyretin, initially increasing FT4 followed by return to normal with possible 30% decrease in total T4.
Source: NLP:levothyroxine sodium
At doses >2 g/day, salicylates inhibit binding of T4 and T3 to TBG and transthyretin, with initial increase in serum FT4 followed by normalization. Total T4 levels may decrease by up to 30%. Closely monitor thyroid parameters.
Source: NLP:liothyronine sodium
Salicylates + MetolazoneModerate
May decrease the antihypertensive effects of metolazone.
Source: NLP:metolazone
Salicylates + Phenytoin SodiumModerate
May increase phenytoin serum levels; monitoring of phenytoin levels recommended.
Source: NLP:extended phenytoin sodium
Salicylates + ProbenecidModerate
Salicylates antagonize the uricosuric action of probenecid.
Source: NLP:probenecid
Salicylates antagonize the uricosuric action of probenecid.
Source: NLP:probenecid and colchicine
Renal clearance of acidic drugs like salicylates may be increased due to alkalinizing action of lactate.
Source: NLP:sodium chloride, sodium lactate, potassium chloride, calcium chloride
Salicylates + Timolol MaleateModerate
High-dose salicylate therapy may cause acid-base and electrolyte disturbances leading to toxicity when combined with dorzolamide.
Source: NLP:ddorzolamide hydrochloride timolol maleate